drugset / Trial / NCT00135343
A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen
RandomizedParallel-groupOpen-label
Summary
The purpose of this study is to evaluate the safety and efficacy of a novel nucleoside sparing regimen containing atazanavir, ritonavir and efavirenz, using two different doses of atazanavir.
Timeline
- Start
- 2004-04
- Primary completion
- 2005-10
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atazanvir | Unknown | 300 mg | Oral |
| Subject | Atazanvir | Unknown | 400 mg | Oral |
| Background | Efavirenz | Other / unclassified | 600 mg | Oral |
| Background | Ritonavir | Other / unclassified | 100 mg | Oral |